EUVIMEDEUVIMED entdecken
Crossref

Nitroreductase‐Responsive Bioorthogonal Tetrazine Conjugations in Cancer Cells

Dan Zhang, Jiaxue Zhang, Hao Liu, Xinyun Ma, Jiaxiang Wang, Hanzeng Cheng, Rui Wang, Luping Liu iD

Chemistry – A European Journal · 2025

DOI: 10.1002/chem.202501592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Dan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Nitroreductases, Prodrugs, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences, CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prodrugs in response to tumor‐overexpressed enzymes offer a targeted approach for cancer therapy. However, this strategy faces several challenges, including poor water solubility, off‐target effects, and tumor heterogeneity. To address these limitations, this study developed a novel class of nitroreductase‐responsive tetrazine precursors by employing nitrobenzyl as a masking group for dihydrotetrazines (NBdTz), which can be further functionalized with targeting peptides. Furthermore, we have demonstrated a dual tumor‐selective on demand bioorthogonal prodrug activation enabled by RGD‐NBdTz. RGD promotes tumor cellular uptake by interacting with tumor‐associated integrin α v β 3 , and subsequent enzymatic reduction of aromatic nitro group of NBdTz by overexpressed Nitroreductase (NTR) among hypoxic tumor microenvironment (TME) leads to the liberation of the bioorthogonal handle tetrazine, resulting in the anticipated bioorthogonal activation of trans ‐cyclooctene caged payloads through “click‐to‐release” reactions. We envision the presented NBdTz enabled tumor‐selective on demand tetrazine ligation offers new opportunities for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroreductasesProdrugsNeoplasmsAntineoplastic AgentsHumansTumor MicroenvironmentCell Line, TumorIntegrin alphaVbeta3Oligopeptides

Stichwörter der Autor:innen

RGDcancer‐targetingnitroreductaseon demand bioorthogonal chemistrytetrazine

Substanzen

NitroreductasesProdrugsIntegrin alphaVbeta3Oligopeptidesarginyl-glycyl-aspartic acidAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.

ORCID-Profile: Luping Liu

Förderung

  • Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China
  • Beijing Nova Program to L. L

Zitieren

APA

Zhang, D., Zhang, J., Liu, H., Ma, X., Wang, J., Cheng, H., Wang, R., & Liu, L. (2025). Nitroreductase‐Responsive Bioorthogonal Tetrazine Conjugations in Cancer Cells. Chemistry – A European Journal. https://doi.org/10.1002/chem.202501592

Vancouver

Zhang D, Zhang J, Liu H, Ma X, Wang J, Cheng H, et al. Nitroreductase‐Responsive Bioorthogonal Tetrazine Conjugations in Cancer Cells. Chemistry – A European Journal. 2025. doi:10.1002/chem.202501592

BibTeX
@article{Zhang2025,
  author = {Zhang, Dan and Zhang, Jiaxue and Liu, Hao and Ma, Xinyun and Wang, Jiaxiang and Cheng, Hanzeng and Wang, Rui and Liu, Luping},
  title = {Nitroreductase‐Responsive Bioorthogonal Tetrazine Conjugations in Cancer Cells},
  journal = {Chemistry – A European Journal},
  year = {2025},
  doi = {10.1002/chem.202501592}
}
Kostenlos starten →